Status:
COMPLETED
Safety and Efficacy in a ReAl-Life Study in Patients With Haemophilia Treated wIth NovoEight® for Surgery
Lead Sponsor:
Nantes University Hospital
Conditions:
Hemophilia
Eligibility:
All Genders
18+ years
Brief Summary
the aim of the SERAPHINE study is to gather data stemming from the French research database BERHLINGO (= Base d'Etude et de Recherche en Hémostase pour Les Investigateurs du Grand-Ouest, i.e. Database...
Eligibility Criteria
Inclusion
- Male or female
- Regardless of age
- No inhibitor (anti-FVIII alloantibodies) at the time of treatment.
- No objections expressed to participate in the study after having been informed of its purposes and the data involved.
- No other inherited hemorrhagic disorders than HA
Exclusion
- In order to reflect the reality of daily practice, no criteria for non-inclusion are provided for other than the refusal of the patient or his or her legal representative to participate in the study or the existence in the patient of a contraindication to the use of turoctocog alfa (NovoEight®) treatment.
Key Trial Info
Start Date :
July 2 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04808349
Start Date
July 2 2021
End Date
June 30 2022
Last Update
November 25 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Angers
Angers, France
2
CH Le Mans
Le Mans, France
3
CHU de Nantes
Nantes, France